Introduction
============

*CD24* is located on chromosome 6q21 and encodes a glycosylphosphatidylinositol-linked cell surface glycoprotein ([@B24]). It is expressed on hematopoietic cells ([@B36]; [@B26]), neural cells ([@B43]), epithelial cells ([@B53]), muscle cells ([@B22]), stem cells ([@B32]; [@B52]), and many other cell types including cancer cells ([@B28]; [@B20]; [@B50]). In addition to the immunological functions ([@B36], [@B35]; [@B38]), recent studies have implicated *CD24* function in tumorigenesis and progression of multiple cancer types, including carcinomas in lung, prostate, ovarian, breast, and brain ([@B28], [@B29]; [@B20]; [@B50]). Cell surface *CD24* has been shown to contribute to tumor metastasis and *Src* oncogene activation. More recently, we and others have reported that *CD24* is translocated to nuclei, where it affects the stability of tumor suppressor gene *P14ARF* and *TP53* ([@B58]). In particular, we have found that *CD24* silencing could prevent functional inactivation of p53 by both somatic mutation and viral oncogenes, and that *TP53* mutated at a higher rate among glioma and prostate cancer samples with higher *CD24* mRNA levels ([@B58]). As a result, several tumor cell lines have been shown to be oncogenic addicted to *CD24* overexpression as their growth and metastasis are diminished upon inactivation of *CD24* expression. However, despite the well-documented function of *CD24* overexpression in tumorigenesis, the driving force of *CD24* overexpression in cancer has not been systematically investigated.

Tumorigenesis is driven by a combination of inherited and acquired genetic alterations. Many studies, including reports from TCGA project, have made use of multiplatform genomic analysis to identify known and new genetic drivers of tumor phenotypes ([@B23]; [@B9]). Copy number variation refers to either extra or missing copies of a gene. Gene copy number amplification is a major genetic mechanism to increase the expression of oncogenes. For example, amplification of *ERBB2*, the gene encoding human epidermal growth factor receptor two, has been reported in approximately 20% of BRCAs and used for therapeutic decision ([@B3]). Likewise, the *MYC* oncogene amplification has been established in numerous cancer types and has emerged as a defining feature for the classification of medulloblastoma ([@B46]). Therefore, it is of considerable interest to determine whether *CD24* is amplified in human cancers, and if so whether such amplification corresponds to *CD24* overexpression and clinical outcome. Here, we investigated the copy number status and expression level of *CD24* in BRCA, ovarian cancer, lung cancer, and prostate cancer. We reported *CD24* amplification in carcinoma of breast, ovarian, lung but not in the prostate, and the copy number amplification was strongly correlated with *CD24* mRNA overexpression, which in turn correlated with signature genes of tumor growth and metastasis. Most importantly, *CD24* gene amplification seemed to be the most impactful genetic alteration for the prognosis of BRCA.

Materials and Methods
=====================

Datasets
--------

We collected the largest publicly available cancer genomics database namely TCGA with genomic, transcriptomic, and clinical data ([Figure 1](#F1){ref-type="fig"}). We accessed the TCGA data portal^[1](#footnote1){ref-type="fn"}^ and downloaded mRNA expression quantification profiles (HTSeq--FPKM) and masked copy number segment profiles for BRCA (*N* = 1082), prostate cancer (*N* = 496), lung squamous cell carcinoma (*N* = 500), and ovarian cancer (*N* = 365). Clinical data files and annotated mutation files of cancer samples were downloaded from cBioPortal for Cancer Genomics^[2](#footnote2){ref-type="fn"}^.

![Illustration of study workflow. The flowchart of data collection and method implementation in this work.](fgene-10-00560-g001){#F1}

Copy Number Analysis
--------------------

GISTIC2 ([@B40]) method was applied to the transformed copy number segment data, with a noise threshold used to determine copy gain or loss. We performed GISTIC version 2.0.22 by using the Homo sapiens (hg38) RefSeq gene annotations^[3](#footnote3){ref-type="fn"}^. The copy number values were obtained by examining the distribution of log2 ratios to identify peaks associated with copy number states. The default GISTIC threshold for identifying gains and losses (0.1 and −0.1, respectively) were used. Other GISTIC parameters were the following: genegistic = 1, maxseg = 2,000, js = 2, cap = 1.5, broad = 1, brlen = 0.7, conf = 0.98, armpeel = 1, rx = 0 and gcm = extreme. The GISTIC algorithm takes into account both high and low thresholds for copy number determination across all the input samples to assign significance to copy number variation. The copy number status of low-level gene amplification, high-level gene amplification, low-level gene deletion, and high-level gene deletion was inferred using the "thresholded" calls.

Gene-Set Enrichment Analysis
----------------------------

Gene-set enrichment analysis was performed with the GSEA program (v. 3.0) ([@B55]). The Broad Molecular Signatures Database (MSigDB v6.0) set H (hallmark gene sets) was used, which summarize and represent specific well-defined biological states or processes. The GSEA program was run with 1,000 permutations for statistical significance estimation, and the default signal-to-noise metric between the two phenotypes was used to rank all genes.

Survival Analysis
-----------------

Univariate and multivariate survival analysis was performed by using the Cox proportional hazard regression model with OS time (5-year) to assess the prognostic value of gene expression, copy number variation, and clinical characteristics ([Figure 1](#F1){ref-type="fig"}). The prognostic value of discrete variables was estimated by Kaplan--Meier survival curves, and the log-rank test was employed to estimate the significance among different survival curves.

Biostatistical Analysis
-----------------------

Data were analyzed by using an unpaired Mann-Whitney test to compare between two groups and one-way analysis of variance (ANOVA) for multiple comparisons. Fisher's exact test was used for enrichment analysis. The Spearman correlation coefficient was performed to estimate the strength and significance of the association between two continuous variables, such as putative copy number values and mRNA expression ([Figure 1](#F1){ref-type="fig"}). For the differential expression analysis, the Mann-Whitney test with multiple testing adjustment (False Discovery Rate, FDR) determined the significant difference. In the graphs, *y*-axis error bars represent median with 95% CI as indicated. Statistical calculations were performed using GraphPad Prism software (GraphPad Software, San Diego, CA) or R Software^[4](#footnote4){ref-type="fn"}^.

Results
=======

*CD24* Overexpression Predicts Adverse Prognosis in BRCA Patients
-----------------------------------------------------------------

We first determined the mRNA expression of *CD24* in BRCA samples from TCGA, which revealed the transcripts of *CD24* were dramatically enhanced in paired BRCA samples (*N* = 112) compared with adjacent breast normal tissues (*P*° \< °0.0001) ([Figure 2A](#F2){ref-type="fig"}). The upregulation was also observed when unpaired tumors were compared with normal samples (*P*° \< °0.0001) ([Supplementary Figure S1A](#SM1){ref-type="supplementary-material"}). Since *CD24* is abundantly expressed in hematopoietic cells, we evaluated whether *CD24* transcripts were affected by the extent of leukocyte infiltration using the common leukocyte antigen *CD45* as a reference. We observed no difference in *CD45* transcripts between *CD24*^high^ and *CD24*^low^ BRCA samples ([Supplementary Figure S1B](#SM1){ref-type="supplementary-material"}). Therefore, the difference in *CD24* transcript levels among BRCA samples was not due to a difference in leukocyte infiltration. Then, we investigated the clinical implication of *CD24* overexpression in BRCA patients. Kaplan--Meier survival analysis revealed that higher *CD24* mRNA expression significantly associated with worse OS in patients with BRCA (*N* = 1079, *P* = 0.0102; [Figure 2B](#F2){ref-type="fig"}). And our *in silico* analysis of the other two independent BRCA cohorts ([@B6]; [@B16]) confirmed this correlation ([Supplementary Figure S1C](#SM1){ref-type="supplementary-material"}). Besides, higher *CD24* expression also predicted poor metastasis-free survival for patients in BRCA metastasis patient cohorts ([@B17]; [@B41]), as evidenced by Kaplan--Meier curves shown in [Supplementary Figure S1D](#SM1){ref-type="supplementary-material"}. In summary, *CD24* is significantly upregulated in BRCA, and its overexpression is an adverse prognostic factor for BRCA patients.

![Correlation between *CD24* copy number alterations and mRNA expression. **(A)** Change of *CD24* mRNA expression between tumor samples and matched normal samples from TCGA BRCA studies (*N* = 112). **(B)** Kaplan--Meier survival curve comparing the high (*N* = 533) and low (*N* = 532) expression value of *CD24* (determined by the median value) for the TCGA BRCA patient cohort. **(C)** GISTIC heat map showing genomic copy-number profiles from TCGA BRCA studies. Gain (red) and loss (blue) of each peak are shown. Regions of copy-number gain (6q21) were highlighted. **(D)** Scatter plot (top) and dot plot (bottom) showing the strong positive correlation between *CD24* copy number values defined by GISTIC2 approach and mRNA expression values quantified by FPKM (*N* = 1082). GISTIC2 method stratified the *CD24* copy number values into five categories: high-level copy number deletion (*N* = 9), low-level copy number deletion (*N* = 326), diploid normal copy (*N* = 548), low-level copy number amplification (*N* = 156), and high-level copy number amplification (*N* = 43). Statistical significance was determined by the Paired *t*-test in panel **(A)**, log-rank test in panel **(B)** and the One-way ANOVA in panel **(D)** (bottom). The Spearman coefficient of correlation (R) and significance in panel **(D)** (top) was determined by linear regression.](fgene-10-00560-g002){#F2}

Copy Number Amplification Correlates to *CD24* Up-Regulation in BRCA
--------------------------------------------------------------------

We interrogated the chromosomal segment value of TCGA BRCA dataset for significant copy number alterations. As expected, our analysis confirmed many known copy number amplifications, including those observed in 3q26.1 (*PIK3CA*) ([@B59]), 8q24.21 (*MYC*) ([@B48]), and 11q13 (*CNCD1*, *EMS1*) ([@B44]). We also observed the chromosomal region of 6q21 (encompassing *CD24*) harbored a major amplification ([Figure 2C](#F2){ref-type="fig"}). And a significant correlation between *CD24* copy number values and mRNA expression was found among all BRCA samples ([Figure 2D](#F2){ref-type="fig"}, *R* = 0.5388, *P*-value \<0.0001). Moreover, we stratified BRCA patients into five groups (High-level Deletion, *N* = 9; Low-level Deletion, *N* = 326; Diploid, *N* = 548; Low-level Amplification, *N* = 156; High-level Amplification, *N* = 43) based on *CD24* copy number values by using GISTIC2 framework. As shown in [Figure 2D](#F2){ref-type="fig"}, approximately one-fifth of all BRCA samples harbored *CD24* amplification, which was on par with *ERBB2* amplification. Consistently, BRCA samples harboring *CD24* amplification exhibited highest mRNA expression than those that exhibit diploid *CD24*, while *CD24* deletion samples had the lowest mRNA expression of *CD24* ([Figure 2D](#F2){ref-type="fig"}). Therefore, the gain of copy number is probably a major mechanism that contributes to the up-regulation of *CD24* in BRCA.

*CD24* Amplification Positively Correlated With Cell Proliferation and *MYC* Signaling Pathway
----------------------------------------------------------------------------------------------

To gain insights into the molecular mechanisms underlying pro-tumorigenic action of *CD24* amplification in BRCA cells, we first analyzed differential gene expression patterns between *CD24* amplified samples (*N* = 199) and *CD24* non-amplified samples (*N* = 883) in TCGA BRCA dataset ([Figure 3A](#F3){ref-type="fig"}). In total, 79 genes were identified as significantly up-regulated genes, which include six genes (*ATG5, C6orf203, QRSL1, PREP, RTN4IP1*, and *AMD1*) located very close to *CD24* genomic region at chromosomal loci. More interesting, we found four cell cycle genes (*CENPW, CDC20, FOXM1*, and *PRP11*) and four cytokeratin genes (*KRT16, KRT6B, KRT17*, and *KRT81*) of these up-regulated expressed genes, which indicating that multiple genes involved in cancer cell proliferation and invasion pathway may be activated concordantly. Besides, several B cell receptor genes were enriched among *CD24*^hi^ BRCA, the significance of such enrichment remains to be elucidated.

![*CD24* amplification correlated with cell cycle and estrogen response activity. **(A)** Volcano plot of mRNA expressions change between BRCA samples harboring *CD24*-amplification and non-*CD24*-amplification. The *x*-axis specifies the fold-changes (FC) and the *y*-axis specifies the negative logarithm to the base 10 of the adjusted *p*-values. Gray vertical and horizontal dashed lines reflect the filtering criteria. Red and green dots represent genes expressed at significantly higher (*n* = °79) or lower (*n* = °68) levels, respectively. The genes located in the 6q21 chromosomal region and enriched in functional patterns are highlighted. **(B)** GSEA comparing gene-expression signatures of TCGA breast tumors with the *CD24*-amplification and non-*CD24*-amplification. GSEA positive result table (top) showing significant enrichment (*FDR* \< 0.05) of the hallmark gene sets from MSigDB. The enrichment plot on the middle left (right, respectively) shows the distribution of MYC targets (G2M checkpoint, respectively) genes that are positively correlated with the *CD24*-amplification phenotype. The distribution plot on the bottom shows the marker genes (*PGK1* and *HMGA1*) expression difference among BRCA patients with different *CD24* copy number status. **(C)** GSEA negative association table (top) showing significant enrichment (*FDR* \< 0.05) of the hallmark gene sets from MSigDB. The enrichment plot on the bottom left shows the distribution of estrogen response early genes that are negatively correlated with the *CD24*-amplification phenotype. The distribution plot on the bottom right shows the marker genes (*ESR1*) expression difference among BRCA patients with different *CD24* copy number status. **(D)** Distribution of ER-negative (based on IHC) samples among different *CD24* copy number groups shows the patients with *CD24*-amplification are enriched in ER-negative status. Normalized enrichment score (NES) and FDR *q*-value of GSEA are shown in panels **(B,C)**. Statistical significance was determined by the One-way ANOVA in panels **(B,C)**, and the exact Fisher's test in panel **(D)**.](fgene-10-00560-g003){#F3}

We further performed gene set enrichment analysis (GSEA) using the MSigDB hallmark gene sets ([@B55]), which revealed that a large number of gene sets were positively enriched in samples harboring *CD24* amplification compared with *CD24* non-amplification samples ([Figure 3B](#F3){ref-type="fig"}). Among the 11 significantly enriched gene sets, the groups of "*MYC* targets" (including V1 and V2), whose expression is connected to c-*Myc*-dependent phenotypes such as cellular proliferation, transformation, or apoptosis, showed particularly strong enrichment, which was confirmed by dramatically up-regulated expression value of *PGK1* ([@B56]), a *MYC* target marker gene, in *CD24* amplification samples (*P* \< 0.0001; [Figure 3B](#F3){ref-type="fig"}). Notably, genes involved in the "G2/M checkpoint" (genes involved in progression through the cell division cycle) and "*E2F* targets" (genes encoding cell cycle related targets of *E2F* transcription factors) were also highly positively enriched in patients harboring *CD24* amplification. As an example, *HMGA1*, an *E2F* target gene that marks the G2M checkpoint ([@B51]), was significant up-regulated *CD24* amplification samples (*P* \< 0.0001; [Figure 3B](#F3){ref-type="fig"}). In summary, these data demonstrate a positive correlation between *CD24* amplification and cell proliferation, a key step in oncogenesis.

*CD24* Amplification Negatively Correlates With Estrogen Response Activity in BRCA
----------------------------------------------------------------------------------

Gene set enrichment analysis showed that only two hallmark gene sets ("estrogen response early" and "estrogen response late") were negatively correlated with *CD24* amplification ([Figure 3C](#F3){ref-type="fig"}). Then we examined the mRNA expression of human ER (*ESR1*) among BRCA patients with different *CD24* copy number status. As shown in [Figure 3C](#F3){ref-type="fig"}, *ESR1* decreased dramatically in BRCA patients harboring *CD24* amplification (*P* \< 0.0001). We further accessed the ER status based on IHC data of TCGA BRCA patients and compared the ER-negative rates among different *CD24* copy number groups. We observed a significantly higher rate of ER-negative patients in *CD24* amplification groups compared with *CD24* diploid and deletion groups ([Figure 3D](#F3){ref-type="fig"}, *P* \< 0.0001).

*CD24* Amplified Samples Exhibit a Selective Increase of *TP53* Mutations
-------------------------------------------------------------------------

To determine whether *CD24* amplification tumors were enriched for the mutations of driver genes, we evaluated its association with the mutation profile of three most commonly altered genes (*PIK3CA, TP53*, and *GATA3*) in BRCA. We used the OncoPrint function of cBioPortal for Cancer Genomics tools^[5](#footnote5){ref-type="fn"}^ to explore the mutation rate of these three genes in TCGA BRCA dataset ([Figure 4A](#F4){ref-type="fig"}). Remarkably, the mutation rate of *TP53* in *CD24* amplified samples is 2.6-fold higher than the non-amplified samples, reaching nearly 65% of the total samples ([Figure 4B](#F4){ref-type="fig"}). In contrast, the *CD24* amplified samples have reduced mutation rate of *PIK3CA* and *GATA3* genes. Nevertheless, there was no hotspot mutation of *TP53* that was specifically enriched in any groups ([Figure 4C](#F4){ref-type="fig"}). These data are consistent with our previous report showing a critical role for *CD24* in inactivation of mutant p53 proteins ([@B58]).

![*TP53* mutation is selectively enriched in *CD24* amplification samples. **(A)** cBioPortal OncoPrint plot showing the distribution of *PIK3CA*, *TP53* and *GATA3* mutation rate in the TCGA BRCA dataset. **(B)** Bar graphs showing the percentage of TCGA BRCA samples with mutations in *PIK3CA, TP53*, and *GATA3* by different *CD24* copy number groups. **(C)** cBioPortal Lollipop plot showing the loci distribution of mutations in *TP53* across TCGA BRCA samples.](fgene-10-00560-g004){#F4}

Prognostic Significance of *CD24* Amplification in BRCA
-------------------------------------------------------

Breast cancer is a heterogeneous disease with diverse pathological features and survival outcomes ([@B54]), and the basal-like or triple-negative BRCAs (TNBCs, lacking expression of the ER, PR and HER2), characterized by a poor prognosis and no specific targeted therapies group ([@B2]). We first investigated the distribution of basal-like patients among different *CD24* copy number groups. As shown in [Figure 5A](#F5){ref-type="fig"}, Basal-like patients were significantly enriched in *CD24* amplification groups compared with *CD24* diploid and deletion groups (both *P* \< 0.0001), which was confirmed by dramatically up-regulated expression of six basal-like genes (*FOXC1* ([@B47]), *VGLL1* ([@B5]), *TTK* ([@B45]), *EGFR* ([@B7]), *KRT6B* ([@B33]), *KRT81* ([@B33]); [Figure 5B](#F5){ref-type="fig"}).

![*CD24* amplification associated with basal-like subtype and poorer survival of BRCA patients. **(A)** Distribution of Basal-like samples among different *CD24* copy number status subtypes of BRCA from TCGA patient cohort. **(B)** Mean value of Basal-like marker genes in BRCA. **(C)** The distribution plot of breast metastasis marker genes expression among BRCA patients with different *CD24* copy number status. **(D)** Kaplan--Meier survival curves comparing the OS and disease-free survival time for different *CD24* copy number subtypes in BRCA. Statistical significance was determined by the exact Fisher's test in panel **(A)**, Wilcoxon test in panel **(B)**, One-way ANOVA in panel **(C)**, and log-rank test in panel **(D)**.](fgene-10-00560-g005){#F5}

We further examined the distribution of three BRCA metastasis marker genes (*CCL18* ([@B8]), *DSC2* ([@B31]) and *HDAC2* ([@B49]); [Figure 5C](#F5){ref-type="fig"}) expression values. Consistent with the correlation between *CD24* amplification and BRCA metastasis ([Supplementary Figure S1D](#SM1){ref-type="supplementary-material"}), the marker genes of BRCA metastasis are significantly up-regulated in *CD24* amplification groups.

To determine if the copy number amplification of *CD24* has prognostic value on the clinical outcome of BRCA patients, we employed a Kaplan--Meier survival analysis for TCGA BRCA patient cohort. As shown in [Figure 5D](#F5){ref-type="fig"}, BRCA patients with the *CD24* amplification had significantly poorer survival rates compared with the *CD24* diploid (*P* = 0.031) and *CD24* deletion (*P* = 0.017) patients. In addition, *CD24 deletion* increased the probability of disease-free survival ([Figure 5D](#F5){ref-type="fig"}).

To further assess the prognostic potential of *CD24* amplification in BRCA, we performed the univariate and multivariate Cox regression analysis, including diagnosis age, tumor subtype, mutation count, *TP53* mutant status and *CD24* expression value. The multivariate result adjusted for standard clinical and pathological parameters confirmed that the impact of *CD24* amplification on OS was independent of BRCA subtype and *TP53* mutant status ([Table 1](#T1){ref-type="table"}). Altogether, the results show that *CD24* amplification is a biomarker to predict both clinical Basal-like stratification and adverse outcome for BRCA patients.

###### 

Cox regression analysis in TCGA BRCA patients.

  **Characteristics**              **Univariate**      **Multivariable**                       
  -------------------------------- ------------------- ------------------- ------------------- ------------
  CD24_CNV (Amp vs. Non-Amp)       1.79 (1.15--2.79)   0.010               1.88 (1.13--3.12)   0.015
  CD24_Expression (High vs. Low)   1.62 (1.07--2.44)   0.022               1.32 (0.83--2.10)   0.243
  CD45_Expression (High vs. Low)   0.66 (0.44--0.98)   0.041               0.69 (0.44--1.06)   0.093
  TP53_Mutation (Mutated vs. WT)   1.35 (0.90--2.03)   0.147                                   
  Patient mutation count           1.00 (1.00--1.00)   0.005               1.00 (1.00--1.00)   0.005
  Diagnosis age                    1.04 (1.02--1.05)   2*e*-06             1.03 (1.02--1.06)   1.78*e*-05
  **Subtype (vs. Luminal)**                                                                    
  Basal-like                       1.38 (0.80--2.39)   0.252                                   
  HER2-enriched                    2.36 (1.26--4.44)   0.007                                   
  Normal-like                      2.04 (0.87--4.76)   0.099                                   

*CD24* Amplification in Prostate, Lung and Ovarian Cancers
----------------------------------------------------------

To determine the general significance of *CD24* amplification and cancer prognosis, we also analyzed the correlation between *CD24* gene copy number and mRNA expression among prostate, lung and ovarian cancer, all known to overexpress *CD24* ([@B19]). As shown in [Figure 6A](#F6){ref-type="fig"}, *CD24* amplification was observed at a high rate among ovarian cancer (20.3%) and lung cancer (19.6%), while prostate cancer rarely (0.4%) showed *CD24* amplification. Nevertheless, a positive correlation was observed between gene copy number and *CD24* mRNA levels. Besides, a strong association was observed between *CD24* amplification and OS of lung cancer patients ([Figure 6B](#F6){ref-type="fig"}). Surprisingly, despite a high rate of *CD24* amplification in ovarian cancer, such amplification has no prognostic value for OS rate ([Figure 6B](#F6){ref-type="fig"}).

![*CD24* amplification in different cancer types. **(A)** Scatter plot (left) and dot plot (right) showing the positive correlation between *CD24* copy number values defined by GISTIC2 approach and mRNA expression values quantified by FPKM in prostate cancer (top), lung squamous cell carcinoma (middle) and ovarian cancer (bottom). **(B)** Kaplan--Meier survival curve comparing the OS time for different *CD24* copy number subtypes in lung squamous cell carcinoma (top) and ovarian cancer (bottom). The Spearman coefficient of correlation (R) and significance in panel **(A)** (left) was determined by linear regression. Statistical significance was determined by the One-way ANOVA in panel **(A)** (right) and log-rank test in panel **(B)**.](fgene-10-00560-g006){#F6}

Discussion
==========

Numerous studies have shown *CD24* overexpression and its prognostic significance in multiple cancer types ([@B29]; [@B19]). However, the cause of *CD24* overexpression remained largely enigmatic. Our analysis presented herein established a strong correlation between *CD24* overexpression and copy number amplification, thus suggested gene amplification as a potential mechanism for *CD24* overexpression. *CD24* plays several critical roles in cancer pathogenesis and cell surface *CD24* has long been associated with cancer metastasis through its role as selectin ligand ([@B1]). Consistently, our data showed *CD24* copy number variation was correlated with expression levels of genes known for their association of cancer metastasis, including *CCL18, HDAC2*, and *DSC2*. *CD24* has oncogenic activity through its regulation of *Src*/*STAT3* pathway ([@B4]). We have reported that *CD24* over-expression is critically important for the inactivation of mutant p53 protein in cancer cells ([@B58]). It followed that cancer samples with most *TP53* mutations must overexpress *CD24*. By showing a 2.6-fold enrichment of *TP53* mutations among *CD24* amplified samples, the data presented here provided further clinical support for the interaction between *CD24* and *TP53* ([@B58]; [@B34]). The high rate of *CD24* amplification among multiple cancer types satisfies major criteria of *CD24* as a *bona fide* oncogene ([@B21]). Obviously, while gene amplification provides a genetic fix that facilitates *CD24* overexpression in the cancer cell, this is not the only mechanism by which *CD24* is induced at high levels among cancer. Only 2/496 prostate cancer patients show *CD24* amplification. Therefore, non-amplification mechanisms, such as activation of HIF1α ([@B57]), may work either independently or in concert with gene amplification to drive a high level of *CD24* expression in cancer.

By comparing the OS of patients with or without *CD24* amplification, we showed that *CD24* amplification was among the most significant genetic prognostic indicator of OS for BRCA patients. Based onHR, the impact of *CD24* amplification (*HR* = 1.79) was considerably stronger than *TP53* mutations (*HR* = 1.35) and basal-like cancer type (*HR* = 1.32). Since the association remains robust and significant in multivariate analysis, *CD24* amplification can be considered as an independent diagnosis marker for BRCA patient prognosis. Besides, *CD24* amplification is enriched in basal-like BRCA patients which has a poorer prognosis, it is of interest to consider whether *CD24* amplification is the driving factor for poor prognosis. We consider *CD24* gene amplification as the primary factor in prognosis as the impact is undiminished after multivariate analysis and its impact is higher than basal-like features. The significance of *CD24* amplification is further enhanced as the frequency of *CD24* amplification is relatively high among major cancer types, including breast (18.4%), ovarian (20.3%), and lung cancer (19.6%). Surprisingly, *CD24* amplification in ovarian cancer does not associate withOS. One potential interpretation may relate to the fact that only intracellular *CD24* appears to affect ovarian cancer survival ([@B28]). Therefore, factors that control *CD24* processing may mask the impact of gene amplification.

To our knowledge, this is the first demonstration of *CD24* copy number amplification during carcinogenesis. Despite functional role for *CD24* in aspects of cancer development, there is no clinical evidence that *CD24* expression is significant enough for cancer ([@B19]; [@B30]). Our analysis revealed, previously undescribed and marked the oncogenic role of *CD24* copy number amplification in the BRCA. It is certainly convinced that the oncogenic features associated with *CD24* amplification cancers could influence response to BRCA treatment strategies. Lacking independent dataset and experimental validation is a limitation to this work, however, given the remarkably *CD24* amplification associated with oncogenic and prognosis signatures, we believe that this phenomenon is generalizable. The future analysis of other datasets with large cancer patients cohort and abundant experimental results will be important to confirm these findings. An increasing amount of evidence demonstrates that non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) ([@B39]; [@B13]) and long non-coding RNAs (lncRNAs) ([@B25]; [@B14]), are aberrantly expressed in several complex diseases, including various cancers. And many high-quality computational inquiries into the genomic investigation of ncRNA--gene-cancer associations ([@B15]; [@B10]; [@B11], [@B12]), revealed the prognosis value and drug target potential for clinical use. There may be many ncRNA-mediated epigenetic changes to *CD24* expression to be discovered in the future, as an important complement to overexpression and copy number amplification, provide a more accurate prediction for clinical outcome. Besides, the machine-based-learning approaches are being developed to aid the diagnosis of clinical samples. A variety of these machine learning techniques, including decision trees, Bayesian networks, support vector machines, and convolutional neural networks have been widely applied in cancer research for the development of predictive models, resulting in effective and accurate decision making ([@B27]; [@B42]; [@B18]; [@B37]). We believe that an approach with integrated molecular feature analysis (like oncogenic copy number amplification analysis) and machine learning prediction models in the future will strengthen the capabilities of cancer diagnosis, prognosis, and even treatment.

Genotyping for *CD24* copy number variation could provide a simple selection or stratification factor to identify populations of interest for cancer risk and treatment subtype, and its exploration as a predictive biomarker is warranted. We believe the *CD24* amplification could serve as a promising therapeutic target and prognosis marker.
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###### 

Correlation between *CD24* copy number alterations and mRNA expression. **(A)** Change of *CD24* mRNA expression between all tumor samples (*N* = 1082) and normal samples (*N* = 112) from TCGA BRCA cancer studies. **(B)** Change of *CD45* mRNA expression between *CD24* higher expression groups (*CD24* exp high, *N* = 541) and *CD24* lower expression samples (*CD24* exp low, *N* = 541) from TCGA BRCA studies. **(C)** Kaplan--Meier OS curves comparing the high and low expression value of *CD24* for two independent BRCA patient cohorts. **(D)** Kaplan--Meier metastasis survival curves comparing the high and low expression value of *CD24* for two independent BRCA patient cohorts. Statistical significance was determined by One-way ANOVA in panel **(A)**, the Wilcoxon test in panel **(B)**, and the log-rank test in panels **(C,D)**.

###### 

Click here for additional data file.
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